dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Valle-T-Figueras, Jose María |
dc.contributor.author | Renedo Miro, Berta |
dc.contributor.author | Díaz de Heredia Rubio, Maria Cristina |
dc.contributor.author | Vima Bofarull, Jaume |
dc.contributor.author | Mendoza Palomar, Natalia Ana |
dc.contributor.author | Martin Gomez, M Teresa |
dc.contributor.author | Soler Palacín, Pere |
dc.contributor.author | Benitez Carabante, Maria Isabel |
dc.date.accessioned | 2022-03-01T07:31:13Z |
dc.date.available | 2022-03-01T07:31:13Z |
dc.date.issued | 2021-06 |
dc.identifier.citation | Valle-T-Figueras JM, Renedo Miró B, Benítez Carabante MI, Díaz-de-Heredia C, Vima Bofarull J, Mendoza-Palomar N, et al. Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment. J Fungi. 2021 Jun;7(6):456. |
dc.identifier.issn | 2309-608X |
dc.identifier.uri | https://hdl.handle.net/11351/7101 |
dc.description | Infecciones fúngicas pediátricas; Monitorización terapéutica de fármacos; Voriconazol |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Fungi;7(6) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antifúngics - Ús terapèutic |
dc.subject | Posologia |
dc.subject | Malalties transmissibles - Tractament |
dc.subject.mesh | Treatment Outcome |
dc.subject.mesh | Antifungal Agents |
dc.subject.mesh | /administration & dosage |
dc.subject.mesh | Communicable Diseases |
dc.title | Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jof7060456 |
dc.subject.decs | resultado del tratamiento |
dc.subject.decs | antifúngicos |
dc.subject.decs | /administración & dosificación |
dc.subject.decs | enfermedades transmisibles |
dc.relation.publishversion | https://doi.org/10.3390/jof7060456 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Valle-T-Figueras JM] Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Paediatrics, Hospital Universitari de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Renedo Miró B] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Benítez Carabante MI, Díaz-de-Heredia C] Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vima Bofarull J] Servei de Bioquímica Clínica, Laboratoris Clínics Centrals, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mendoza-Palomar N, Soler-Palacín P] Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Martín-Gómez MT] Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
dc.identifier.pmid | 34200506 |
dc.identifier.wos | 000666633900001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |